Want to Know More About Medical Isotopes?
The Canadian Agency for Drugs and Technologies in Health (CADTH) is undertaking a multifaceted project to support greater efficiency and effectiveness in the health system management of the medical isotope technetium-99m (99mTc).
In light of recent global supply disruption of 99mTc, CADTH will be developing guidance on how to prioritize the use of this medical isotope. The evaluation will also assess how 99mTc compares with other medical imaging options, such as magnetic resonance imaging (MRI) or other medical isotopes.
The goal of the project is to provide Canadian health care decision-makers with evidence-based guidance on policies, protocols, and standards related to 99mTc. This will help support optimal access to appropriate medical imaging for Canadians.
- Find out more in the Project Backgrounder.
- Learn about the Medical Isotopes and Imaging Modalities Advisory Committee (MIIMAC), comprising experts from across Canada, who will help CADTH provide guidance on optimizing the use of medical isotopes.